// App-Quantinova.ai

3226 : Efficacy of PD-1 - PD-L1 pathway disruptors in syngeneic models

Researchers

Presenter

  • Anais Lagrange

Principal Investigators

  • Romain Boidot

  • Marc Hillairet de Boisferon

  • Olivier Duchamp

  • Jean-Francois Mirjolet

  • Francois Ghiringhelli

Medical Centers

  • INSERM , Dijon, France

  • Center Georges-Francois Leclerc, Dijon, France

  • Oncodesign S.A., Dijon Cedex, France

  • INSERM / Centre Georges Francois Leclerc, Dijon, France.

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Mismatch repair deficiency

  • Small cell lung cancer

  • Colorectal Cancer

  • Renal cell carcinoma

  • Melanoma

  • Hodgkin's Lymphoma

  • Lung Cancer

  • Solid malignancies

  • Lymphomas

Biomarkers

  • Cluster of Differentiation 206

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved